According to a report by the Wall Street Journal, Merck & Co. has ceased discussions to acquire cancer‐drug developer Revolution Medicines. Earlier indications suggested Merck was prepared to pay roughly $30 billion for the oncology biotech, which is developing targeted therapies for RAS-driven tumors. The breakdown in talks removes a potential bolt-on transaction that analysts had flagged as a strategic accelerant for Merck’s oncology pipeline, particularly as Keytruda sales growth moderates and competition intensifies in immuno-oncology.

In the most recent regulatory filings, Cullen Frost Bankers Inc. reduced its Merck shareholding by 7.0%, selling 17,082 shares and leaving it with 225,581 shares valued at approximately $19 million. Other large investors made notable moves in the prior quarter: Charles Schwab Investment Management added 4.6 million shares (a 9.4% increase), DLD Asset Management and Norges Bank each initiated new positions worth nearly $2.9 billion, and Franklin Resources boosted its stake by 23.5% (5.1 million shares). These shifts reflect divergent views on Merck’s valuation amid its late-stage pipeline readouts and broader market rotations.

In its February earnings release, Merck reported quarterly earnings per share of $1.94, falling short of consensus estimates by $0.14. The company recorded a return on equity of 44.5% and a net margin near 29.6%. Concurrently, Merck announced an increase in its quarterly dividend from $0.81 to $0.85, equating to a $3.40 annualized payout and a yield of roughly 3.1%. Management indicated confidence in cash flow generation from flagship products such as Keytruda, while noting that investment in new pipeline assets will remain a priority for sustaining long-term growth.